pharmaceuticals Archives - Page 4 of 5

RAP Pharma International има верига от 10 аптеки в Молдова.

Sopharma acquired majority stake in Moldavian distributor RAP Pharma International

18 April 2017

Sopharma acquired 51% of the Moldavian pharma distributor RAP Pharma International, after approval by the Committee for protection of competition in Moldova, informed investor.bg quoting a public announcement by the company.

New research report: Sopharma finally catches the tailwinds

7 April 2017

Sopharma – the leading generic pharmaceutical company in Bulgaria – booked a 2016 performance in line with ELANA Trading analysts’ expectations. Top line negative surprises seem fading away, operating profits sustained on cost optimization and profitable divestments made the bottom line. Sales in line with analysts’ expectations After losing a quarter of its operations due… Read more

Mareshki, leader of Bulgarian nationalists’ party, lists a pharma company Pharmhold

30 March 2017

Veselin Mareshki, leader of the Bulgarian nationalists’ party, lists Pharmhold (2PH BU), according to a notice by the Bulgarian Stock Exchange. Mareshki road to listing The Company has been aiming to list since 2015. Finally it received the right to apply for listing after battling the regulator’s denial to approve it as a public company… Read more

Medica and Sopharma signed a revised merger agreement

24 March 2017

Leading generic pharma producer Sopharma (3JR BU) and medical consumables producer Medica (5MA BU) signed a revised merger agreement, according to a regulatory filing with the stock exchange. Medica shareholders are getting 0.8831 Sopharma shares The revised agreement followed recommendations from the Financial Supervision Commission (FSC) based on the initial agreement filed for approval. Both… Read more

Sopharma Trading to expand faster via acquisitions in Bulgaria and Serbia

16 March 2017

Bulgarian drug distributor Sopharma Trading (SO5 BU) scheduled an extraordinary shareholders meeting for 24th April 2017 to approve new debt financing from various banks for a total of approx.. BGN 54m to be used for acquisitions in Bulgaria and Serbia, according to a regulatory filing. The loans in plan of Sopharma Trading EUR 12 mln.… Read more

Sopharma CEO Ognyan Donev: Good news from US continues

8 March 2017

Leading generic pharma producer in Bulgaria – Sopharma (3JR BU), booked 8% y/y rise in sales for Jan-Feb 2017 and announced new move forward in a smoking cessation drug registration in the US in a release published on the Bulgarian Stock Exchange, quoting CEO Ognyan Donev. Pleasing results from Russia The Company announced exports advanced… Read more

Sopharma acquires Moldavian distributor RAP Pharma

28 February 2017

Leading pharma group in Bulgaria Sopharma receive a regulatory nod to acquire a Moldova pharma distributor, the Company announced in a statement to the stock exchange. Deal parameters to be known when the transaction is finalized. The Moldavian antitrust regulator approved Sopharma to acquire over 51% in RAP Pharma International. RAP Pharma operates retail chain… Read more

Sopharma booked best FY2016 net profit in 3 years

1 February 2017

Leading generic pharma producer Sopharma met top line estimates but missed profit expectation on new impairments – the Company published its unconsolidated unaudited FY2016 financial statements. Sopharma FY2016 meets some of the estimates Sopharma booked best FY2016 net profit in three years both on one off and cost optimizations. Net income came at BGN 37.3m,… Read more

Sopharma drug closer to US registration

9 January 2017

Sopharma’s smoking cessation drug closer to a US registration. The drug, known and sold by Sopharma under the Tabex brand in Central and Eastern Europe, is currently in a final Phase 3 trial conducted by the US based private company Achieve Life Science Inc. Achieve acquired the right to sell it in the US, Mexico,… Read more

Sopharma Trading top line expansion slows down in Q3 2016, Q4 acceleration expected

22 December 2016

Leading pharma distributor in Bulgaria, Sopharma Trading, booked third consecutive quarter of slower than expected growth. In 3Q16, top line growth turned negative of 1.63% y/y to BGN 150m on higher 3Q15 base when the Company had major big medical equipment deals. Overall, 9M16 sales are down 0.34% y/y to BGN 447.7m on all segments – pharmacies, hospitals, wholesale and big medical equipment deals, slower than expected.